Healthpeak Properties Inc. Common Stock vs Neurocrine Biosciences Inc — how do they compare? Healthpeak Properties Inc. Common Stock trades at $18.55 (market cap $12.77B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: Healthpeak Properties Inc. Common Stock and Neurocrine Biosciences Inc are close in size by market cap, and Healthpeak Properties Inc. Common Stock pays a 6.59% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Healthpeak Properties Inc. Common Stock for 0 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DOC | NBIX | |
|---|---|---|
Market Cap | $12.77B | $14.36B |
Volume | 11,021,809 | 1,237,180 |
Sector | Real Estate | Health |
52-Week High | $22.82 | $185.50 |
52-Week Low | $15.78 | $123.10 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $21.46B | $14.37B |
Dividend Yield | 6.59% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Healthpeak Properties is a healthcare real estate investment trust in the United States. It owns, operates, and develops outpatient medical, laboratory, and senior housing properties.
Read more on DOC →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →